|
業務類別
|
Biotechnology |
|
業務概覽
|
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA. |
| 公司地址
| 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4 |
| 電話號碼
| +1 250 590-3968 |
| 傳真號碼
| +1 250 590-2588 |
| 公司網頁
| https://www.eupraxiapharma.com |
| 員工數量
| 49 |
| Mr. Paul Brennan |
Chief Business Officer |
美元 253.97K |
13/03/2026 |
| Dr. Mark Kowalski, M.D.,Pd.D |
Chief Medical Officer |
美元 435.00K |
13/03/2026 |
| Dr. James A. Helliwell, M.D. |
Chief Executive Officer and Director |
美元 429.25K |
13/03/2026 |
| Dr. Amanda Malone |
Chief Scientific Officer and Chief Operating Officer |
美元 329.09K |
13/03/2026 |
| Mr. Alexander Rothwell |
Chief Financial Officer |
美元 287.95K |
13/03/2026 |
|
|
| Dr. Richard M. Glickman,L.L.D. |
Independent Director |
13/03/2026 |
| Mr. Paul L. Geyer, P. Eng. |
Independent Director |
13/03/2026 |
| Mr. Joseph Freedman, L.L.B.,M.B.A. |
Director |
13/03/2026 |
| Mr. Robert B. Bazemore, Jr |
Director |
13/03/2026 |
| Dr. Simon Pimstone, F.R.C.P.C,M.D.,PhD |
Chairman of the Board |
13/03/2026 |
| Mr. John S. Montalbano, C.F.A. |
Independent Director |
13/03/2026 |
| Ms. Amy Pott |
Director |
13/03/2026 |
| Dr. James A. Helliwell, M.D. |
Chief Executive Officer and Director |
13/03/2026 |
| Dr. Michael Wilmink, M.D. |
Independent Director |
13/03/2026 |
|
|
|
|